CSI Market
Sign In | Register

Kymera Therapeutics Inc (KYMR) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access KYMR quarterly Cash Flow →
The cash flow figures below highlight longer-term patterns in how Kymera Therapeutics Inc manages cash inflows and outflows over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-311.35
Depreciation & amortization8.31
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Long-Lived Assets to be Disposed of3.86
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation59.90
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Non Cash Research And Development Expense-
Increase Decrease In Contract With Customer Asset Related Parties0.95
Increase Decrease In Contract With Customer Liability20.79
Increase Decrease In Operating Lease Right Of Use Assets2.67
Premiums And Discounts On Available For Sale Marketable Securities-8.88
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Due from Related Parties0.00
Increase (Decrease) in Accounts Payable-1.97
Increase (Decrease) in Accrued Liabilities7.39
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-2.36
Other Working Capital-7.15
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-5.04
Discontinued operations0.00
Net Cash flow from Operating Activities-232.89
Investing Activities
Capital Expenditures-1.45
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities488.02
Payments to Acquire Marketable Securities-1,007.63
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-521.06
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-1.49
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock61.62
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net928.90
Payments For Proceeds From Stock Option Exercises-
Proceeds From Concurrent Private Placement-
Restricted Cash And Cash Equivalents-
Issuance Of Common Stock And Accompanying Pre Funded Warrants At Private Placement Net Of Issuance Costs-
Proceeds From Follow On Offering Net Of Underwriting Discounts And Offering Costs-
Proceeds From Concurrent Private Placement Follow On-
Proceeds From Employee Stock Purchase Plan1.69
Issuance Of Common Stock At Private Placement Net Of Issuance Cost-
Issuance Of Common Stock And Accompanying Pre Funded Warrants From August Two Thous and Twenty Four Public Offering Net Of Issuance Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities990.71
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-234.34
Total Cash Flow236.76
4 historic quarters locked

Sign in to unlock the full Kymera Therapeutics Inc cash flow history.

Sign In Create Free Account

About Kymera Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 26, 2026
  • Source: kymr-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-073395

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License